Potential utility of full-spectrum antioxidant therapy, citrulline, and dietary nitrate in the management of sickle cell disease

Medical Hypotheses

Volumn 74, Issue 6, 2010, Pages 1055-1058

  McCarty, Mark F ^a  

^a NutriGuard Research   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; ANTIOXIDANT; ARGINASE; ARGININE; BILIRUBIN; BILIVERDIN; CITRULLINE; FOLIC ACID; GLUTATHIONE; HEMOGLOBIN; HYDROXYUREA; ICARIIN; N(G),N(G) DIMETHYLARGININE; NITRATE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; NUTRACEUTICAL; PENTOXIFYLLINE; PEROXYNITRITE; PHOSPHODIESTERASE V INHIBITOR; PLACEBO; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; SILDENAFIL; SPIRULINA EXTRACT; THIOCTIC ACID;

ANTIOXIDANT ACTIVITY; ARTICLE; CLINICAL TRIAL; DIET SUPPLEMENTATION; ENZYME ACTIVITY; ENZYME INHIBITION; EPIMEDIUM; ERECTILE DYSFUNCTION; FOOD INTAKE; GLUTATHIONE METABOLISM; HUMAN; MEDICAL DECISION MAKING; NONHUMAN; OXIDATIVE STRESS; PROTEIN EXPRESSION; PULMONARY HYPERTENSION; SICKLE CELL ANEMIA; VASCULAR ENDOTHELIUM; VEGETABLE;

ANEMIA, SICKLE CELL; ANIMALS; ANTIOXIDANTS; ARGININE; CITRULLINE; HEMOGLOBINS; HUMANS; MODELS, BIOLOGICAL; NITRATES; NITRIC OXIDE; OXIDATIVE STRESS; VEGETABLES;

SPIRULINA;

EID: 77951622606     PISSN: 03069877     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mehy.2009.12.020     Document Type: Article

References (69)

1. Wood K.C., Hsu L.L., Gladwin M.T. Sickle cell disease vasculopathy: a state of nitric oxide resistance. Free Radic Biol Med 2008, 44(8):1506-1528.
2. Morris C.R. Mechanisms of vasculopathy in sickle cell disease and thalassemia. Hematol Am Soc Hematol Educ Program 2008, 177-185.
3. McCarty M.F., Barroso-Aranda J., Contreras F. High-dose folate and dietary purines promote scavenging of peroxynitrite-derived radicals - clinical potential in inflammatory disorders. Med Hypotheses 2009, 73(5):824-834.
4. McCarty MF. The Oasis Executive Health Program. 2009. Ref Type: Unpublished Work.
5. McCarty M.F. Clinical potential of Spirulina as a source of phycocyanobilin. J Med Food 2007, 10(4):566-570.
6. Lanone S., Bloc S., Foresti R., Almolki A., Taille C., Callebert J., et al. Bilirubin decreases nos2 expression via inhibition of NAD(P)H oxidase: implications for protection against endotoxic shock in rats. FASEB J 2005, 19(13):1890-1892.
7. Matsumoto H., Ishikawa K., Itabe H., Maruyama Y. Carbon monoxide and bilirubin from heme oxygenase-1 suppresses reactive oxygen species generation and plasminogen activator inhibitor-1 induction. Mol Cell Biochem 2006, 291(1-2):21-28.
8. Jiang F., Roberts S.J., Datla S., Dusting G.J. NO modulates NADPH oxidase function via heme oxygenase-1 in human endothelial cells. Hypertension 2006, 48(5):950-957.
9. Wood K.C., Hebbel R.P., Granger D.N. Endothelial cell NADPH oxidase mediates the cerebral microvascular dysfunction in sickle cell transgenic mice. FASEB J 2005, 19(8):989-991.
10. Belcher J.D., Mahaseth H., Welch T.E., Otterbein L.E., Hebbel R.P., Vercellotti G.M. Heme oxygenase-1 is a modulator of inflammation and vaso-occlusion in transgenic sickle mice. J Clin Invest 2006, 116(3):808-816.
11. Romay C., Gonzalez R., Ledon N., Remirez D., Rimbau V. C-phycocyanin: a biliprotein with antioxidant, anti-inflammatory and neuroprotective effects. Curr Protein Pept Sci 2003, 4(3):207-216.
12. Chamorro G., Perez-Albiter M., Serrano-Garcia N., Mares-Samano J.J., Rojas P. Spirulina maxima pretreatment partially protects against 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine neurotoxicity. Nutr Neurosci 2006, 9(5-6):207-212.
13. Riss J., Decorde K., Sutra T., Delage M., Baccou J.C., Jouy N., et al. Phycobiliprotein C-phycocyanin from Spirulina platensis is powerfully responsible for reducing oxidative stress and NADPH oxidase expression induced by an atherogenic diet in hamsters. J Agric Food Chem 2007, 55(19):7962-7967.
14. Rezk B.M., Haenen G.R., van der Vijgh W.B., Bast A. Tetrahydrofolate and 5-methyltetrahydrofolate are folates with high antioxidant activity Identification of the antioxidant pharmacophore. FEBS Lett 2003, 555(3):601-605.
15. Antoniades C., Shirodaria C., Warrick N., Cai S., de B.J., Lee J., et al. 5-methyltetrahydrofolate rapidly improves endothelial function and decreases superoxide production in human vessels: effects on vascular tetrahydrobiopterin availability and endothelial nitric oxide synthase coupling. Circulation 2006, 114(11):1193-1201.
16. Verhaar M.C., Wever R.M., Kastelein J.J., van D.T., Koomans H.A., Rabelink T.J. 5-Methyltetrahydrofolate, the active form of folic acid, restores endothelial function in familial hypercholesterolemia. Circulation 1998, 97(3):237-241.
17. Stroes E.S., van Faassen E.E., Yo M., Martasek P., Boer P., Govers R., et al. Folic acid reverts dysfunction of endothelial nitric oxide synthase. Circ Res 2000, 86(11):1129-1134.
18. Hyndman M.E., Verma S., Rosenfeld R.J., Anderson T.J., Parsons H.G. Interaction of 5-methyltetrahydrofolate and tetrahydrobiopterin on endothelial function. Am J Physiol Heart Circ Physiol 2002, 282(6):H2167-H2172.
19. Moens A.L., Claeys M.J., Wuyts F.L., Goovaerts I., Van H.E., Wendelen L.C., et al. Effect of folic acid on endothelial function following acute myocardial infarction. Am J Cardiol 2007, 99(4):476-481.
20. Wood K.C., Hebbel R.P., Lefer D.J., Granger D.N. Critical role of endothelial cell-derived nitric oxide synthase in sickle cell disease-induced microvascular dysfunction. Free Radic Biol Med 2006, 40(8):1443-1453.
21. Moens A.L., Champion H.C., Claeys M.J., Tavazzi B., Kaminski P.M., Wolin M.S., et al. High-dose folic acid pretreatment blunts cardiac dysfunction during ischemia coupled to maintenance of high-energy phosphates and reduces postreperfusion injury. Circulation 2008.
22. Guzy R.D., Schumacker P.T. Oxygen sensing by mitochondria at complex III: the paradox of increased reactive oxygen species during hypoxia. Exp Physiol 2006, 91(5):807-819.
23. Franco R., Schoneveld O.J., Pappa A., Panayiotidis M.I. The central role of glutathione in the pathophysiology of human diseases. Arch Physiol Biochem 2007, 113(4-5):234-258.
24. Atkuri K.R., Mantovani J.J., Herzenberg L.A., Herzenberg L.A. N-Acetylcysteine-a safe antidote for cysteine/glutathione deficiency. Curr Opin Pharmacol 2007, 7(4):355-359.
25. Dodd S., Dean O., Copolov D.L., Malhi G.S., Berk M. N-acetylcysteine for antioxidant therapy: pharmacology and clinical utility. Expert Opin Biol Ther 2008, 8(12):1955-1962.
26. Surh Y.J., Kundu J.K., Na H.K. Nrf2 as a master redox switch in turning on the cellular signaling involved in the induction of cytoprotective genes by some chemopreventive phytochemicals. Planta Med 2008, 74(13):1526-1539.
27. Li M., Chiu J.F., Kelsen A., Lu S.C., Fukagawa N.K. Identification and characterization of an Nrf2-mediated ARE upstream of the rat glutamate cysteine ligase catalytic subunit gene (GCLC). J Cell Biochem 2009, 107(5):944-954.
28. Shartava A., Shah A.K., Goodman S.R. N-acetylcysteine and clotrimazole inhibit sickle erythrocyte dehydration induced by 1-chloro-2, 4-dinitrobenzene. Am J Hematol 1999, 62(1):19-24.
29. Pace B.S., Shartava A., Pack-Mabien A., Mulekar M., Ardia A., Goodman S.R. Effects of N-acetylcysteine on dense cell formation in sickle cell disease. Am J Hematol 2003, 73(1):26-32.
30. Chen X.L., Kunsch C. Induction of cytoprotective genes through Nrf2/antioxidant response element pathway: a new therapeutic approach for the treatment of inflammatory diseases. Curr Pharm Des 2004, 10(8):879-891.
31. Ziegler D., Ametov A., Barinov A., Dyck P.J., Gurieva I., Low P.A., et al. Oral treatment with alpha-lipoic acid improves symptomatic diabetic polyneuropathy: the SYDNEY 2 trial. Diabetes Care 2006, 29(11):2365-2370.
32. Flier J., Van Muiswinkel F.L., Jongenelen C.A., Drukarch B. The neuroprotective antioxidant alpha-lipoic acid induces detoxication enzymes in cultured astroglial cells. Free Radic Res 2002, 36(6):695-699.
33. Cao Z., Tsang M., Zhao H., Li Y. Induction of endogenous antioxidants and phase 2 enzymes by alpha-lipoic acid in rat cardiac H9C2 cells: protection against oxidative injury. Biochem Biophys Res Commun 2003, 310(3):979-985.
34. Jia Z., Hallur S., Zhu H., Li Y., Misra H.P. Potent upregulation of glutathione and NAD(P)H:quinone oxidoreductase 1 by alpha-lipoic acid in human neuroblastoma SH-SY5Y cells: protection against neurotoxicant-elicited cytotoxicity. Neurochem Res 2008, 33(5):790-800.
35. Dulundu E., Ozel Y., Topaloglu U., Sehirli O., Ercan F., Gedik N., et al. Alpha-lipoic acid protects against hepatic ischemia-reperfusion injury in rats. Pharmacology 2007, 79(3):163-170.
36. Cosar E., Sahin F.K., Koken G., Toy H., Basarali K., Buyukbas S. The protective effect of alpha-lipoic acid in experimental ovarian ischaemia-reperfusion injury. Aust N Z J Obstet Gynaecol 2007, 47(6):499-503.
37. Bae E.H., Lee K.S., Lee J., Ma S.K., Kim N.H., Choi K.C., et al. Effects of alpha-lipoic acid on ischemia-reperfusion-induced renal dysfunction in rats. Am J Physiol Renal Physiol 2008, 294(1):F272-F280.
38. Guven A., Tunc T., Topal T., Kul M., Korkmaz A., Gundogdu G., et al. Alpha-lipoic acid and ebselen prevent ischemia/reperfusion injury in the rat intestine. Surg Today 2008, 38(11):1029-1035.
39. Tunc T., Oter S., Guven A., Topal T., Kul M., Korkmaz A., et al. Protective effect of sulfhydryl-containing antioxidants against ischemia/reperfusion injury of prepubertal rat intestine. J Gastroenterol Hepatol 2009, 24(4):681-687.
40. Sivaprasad R., Nagaraj M., Varalakshmi P. Combined efficacies of lipoic acid and meso-2, 3-dimercaptosuccinic acid on lead-induced erythrocyte membrane lipid peroxidation and antioxidant status in rats. Hum Exp Toxicol 2003, 22(4):183-192.
41. Malarkodi K.P., Sivaprasad R., Varalakshmi P. Effect of lipoic acid on the oxidoreductive status of red blood cells in rats subject to oxidative stress by chronic administration of adriamycin. Hum Exp Toxicol 2004, 23(3):129-135.
42. Caylak E., Aytekin M., Halifeoglu I. Antioxidant effects of methionine, alpha-lipoic acid, N-acetylcysteine and homocysteine on lead-induced oxidative stress to erythrocytes in rats. Exp Toxicol Pathol 2008, 60(4-5):289-294.
43. Martins V.D., Manfredini V., Peralba M.C., Benfato M.S. Alpha-lipoic acid modifies oxidative stress parameters in sickle cell trait subjects and sickle cell patients. Clin Nutr 2009, 28(2):192-197.
44. Morris C.R., Kato G.J., Poljakovic M., Wang X., Blackwelder W.C., Sachdev V., et al. Dysregulated arginine metabolism, hemolysis-associated pulmonary hypertension, and mortality in sickle cell disease. JAMA 2005, 294(1):81-90.
45. Morris C.R., Kuypers F.A., Larkin S., Vichinsky E.P., Styles L.A. Patterns of arginine and nitric oxide in patients with sickle cell disease with vaso-occlusive crisis and acute chest syndrome. J Pediatr Hematol Oncol 2000, 22(6):515-520.
46. Schnog J.B., Teerlink T., van der Dijs F.P., Duits A.J., Muskiet F.A. Plasma levels of asymmetric dimethylarginine (ADMA), an endogenous nitric oxide synthase inhibitor, are elevated in sickle cell disease. Ann Hematol 2005, 84(5):282-286.
47. Cooke J.P., Oka R.K. Atherogenesis and the arginine hypothesis. Curr Atheroscler Rep 2001, 3(3):252-259.
48. Cooke J.P. ADMA: its role in vascular disease. Vasc Med 2005, 10(Suppl. 1):S11-S17.
49. Schwedhelm E., Maas R., Freese R., Jung D., Lukacs Z., Jambrecina A., et al. Pharmacokinetic and pharmacodynamic properties of oral L-citrulline and L-arginine: impact on nitric oxide metabolism. Br J Clin Pharmacol 2008, 65(1):51-59.
50. Waugh W.H., Daeschner C.W., Files B.A., McConnell M.E., Strandjord S.E. Oral citrulline as arginine precursor may be beneficial in sickle cell disease: early phase two results. J Natl Med Assoc 2001, 93(10):363-371.
51. Waugh W.H. Arginine metabolism, pulmonary hypertension, and sickle cell disease. JAMA 2005, 294(19):2432-2433.
52. Goodwin B.L., Solomonson L.P., Eichler D.C. Argininosuccinate synthase expression is required to maintain nitric oxide production and cell viability in aortic endothelial cells. J Biol Chem 2004, 279(18):18353-18360.
53. Flam B.R., Eichler D.C., Solomonson L.P. Endothelial nitric oxide production is tightly coupled to the citrulline-NO cycle. Nitric oxide 2007, 17(3-4):115-121.
54. Mack A.K., Gowan Ii V.R., Tremonti C.K., Ackah D., Barnett C., Machado R.F., et al. Sodium nitrite promotes regional blood flow in patients with sickle cell disease: a phase I/II study. Br J Haematol 2008, 142(6):971-978.
55. Kato G.J., Gladwin M.T. Evolution of novel small-molecule therapeutics targeting sickle cell vasculopathy. JAMA 2008, 300(22):2638-2646.
56. Hord N.G., Tang Y., Bryan N.S. Food sources of nitrates and nitrites: the physiologic context for potential health benefits. Am J Clin Nutr 2009, 90(1):1-10.
57. Webb A.J., Patel N., Loukogeorgakis S., Okorie M., Aboud Z., Misra S., et al. Acute blood pressure lowering, vasoprotective, and antiplatelet properties of dietary nitrate via bioconversion to nitrite. Hypertension 2008, 51(3):784-790.
58. Strouse J.J., Lanzkron S., Beach M.C., Haywood C., Park H., Witkop C., et al. Hydroxyurea for sickle cell disease: a systematic review for efficacy and toxicity in children. Pediatrics 2008, 122(6):1332-1342.
59. Ambrus J.L., Ambrus C.M., Bannerman R., Sills R.H., Meky N.N. Studies on the management and prevention of vasoocclusive crisis in sickle cell disease. J Med 1984, 15(5-6):385-407.
60. Manrique R.V. Placebo controlled double-blind study of pentoxifylline in sickle cell disease patients. J Med 1987, 18(5-6):277-291.
61. Stuart J., Stone P.C., Bilto Y.Y., Keidan A.J. Oxpentifylline and cetiedil citrate improve deformability of dehydrated sickle cells. J Clin Pathol 1987, 40(10):1182-1186.
62. Ambrus J.L., Reddington T.M., Meky N.N., Conway J. " Stiff red cell syndrome" A review of the treatment of sickle cell disease with pentoxifylline. J Med 1993, 24(1):1-9.
63. Sacerdote A. Treatment of homozygous sickle cell disease with pentoxifylline. J Natl Med Assoc 1999, 91(8):466-470.
64. Dettelbach H.R., Aviado D.M. Clinical pharmacology of pentoxifylline with special reference to its hemorrheologic effect for the treatment of intermittent claudication. J Clin Pharmacol 1985, 25(1):8-26.
65. Kato G.J. Novel small molecule therapeutics for sickle cell disease: nitric oxide, carbon monoxide, nitrite, and apolipoprotein A-I. Hematology Am Soc Hematol Educ Program 2008, 186-192.
66. Little J.A., Hauser K.P., Martyr S.E., Harris A., Maric I., Morris C.R., et al. Hematologic, biochemical, and cardiopulmonary effects of L-arginine supplementation or phosphodiesterase 5 inhibition in patients with sickle cell disease who are on hydroxyurea therapy. Eur J Haematol 2009, 82(4):315-321.
67. Jiang Z., Hu B., Wang J., Tang Q., Tan Y., Xiang J., et al. Effect of icariin on cyclic GMP levels and on the mRNA expression of cGMP-binding cGMP-specific phosphodiesterase (PDE5) in penile cavernosum. J Huazhong Univ Sci Technolog Med Sci 2006, 26(4):460-462.
68. Liu W.J., Xin Z.C., Xin H., Yuan Y.M., Tian L., Guo Y.L. Effects of icariin on erectile function and expression of nitric oxide synthase isoforms in castrated rats. Asian J Androl 2005, 7(4):381-388.
69. Xin Z.C., Kim E.K., Lin C.S., Liu W.J., Tian L., Yuan Y.M., et al. Effects of icariin on cGMP-specific PDE5 and cAMP-specific PDE4 activities. Asian J Androl 2003, 5(1):15-18.